摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-[[[(ferrocenylamino)carbonyl]oxy]methyl]-phenol acetate | 1398039-52-5

中文名称
——
中文别名
——
英文名称
4-[[[(ferrocenylamino)carbonyl]oxy]methyl]-phenol acetate
英文别名
——
4-[[[(ferrocenylamino)carbonyl]oxy]methyl]-phenol acetate化学式
CAS
1398039-52-5
化学式
C20H19FeNO4
mdl
——
分子量
393.222
InChiKey
SLMHVIMKEBHUEQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    None
  • 重原子数:
    None
  • 可旋转键数:
    None
  • 环数:
    None
  • sp3杂化的碳原子比例:
    None
  • 拓扑面积:
    None
  • 氢给体数:
    None
  • 氢受体数:
    None

反应信息

  • 作为产物:
    参考文献:
    名称:
    [EN] FERROCENE-BASED COMPOUNDS AND THEIR USE AS ROS REGULATING PRODRUGS
    [FR] COMPOSÉS À BASE DE FERROCÈNE ET LEUR UTILISATION COMME PROMÉDICAMENTS RÉGULANT LES ESPÈCES RÉACTIVES DE L'OXYGÈNE (ROS)
    摘要:
    本发明涉及基于二茂铁的化合物及其作为活性氧(ROS,反应性氧种)调节前药的使用。特别是,本发明涉及在激活时作为增加细胞氧化应激的ROS调节前药的基于二茂铁的化合物。
    公开号:
    WO2012123076A1
点击查看最新优质反应信息

文献信息

  • Aminoferrocene-Based Prodrugs and Their Effects on Human Normal and Cancer Cells as Well as Bacterial Cells
    作者:Paul Marzenell、Helen Hagen、Leopold Sellner、Thorsten Zenz、Ruta Grinyte、Valeri Pavlov、Steffen Daum、Andriy Mokhir
    DOI:10.1021/jm400754c
    日期:2013.9.12
    Aminoferrocene-based prodrugs are activated under cancer-specific conditions (high concentration of reactive oxygen species, ROS) with the formation of glutathione scavengers (p-quinone methide) and ROS-generating iron complexes. Herein, we explored three structural modifications of these prodrugs in an attempt to improve their properties: (a) the attachment of a -COOH function to the ferrocene fragment leads to the improvement of water solubility and reactivity in vitro but also decreases cell-membrane permeability and biological activity, (b) the alkylation of the N-benzyl residue does not show any significant affect, and (c) the attachment of the second arylboronic acid fragment improves the toxicity (IC50) of the prodrugs toward human promyelocytic leukemia cells (HL-60) from 52 to 12 mu M. Finally, we demonstrated that the prodrugs are active against primary chronic lymphocytic leukemia (CLL) cells, with the, best compounds exhibiting an IC50 value of 1.5 mu M. The most active compounds were found to not affect mononuclear cells and representative bacterial cells.
查看更多